Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC) is indicated to relieve redness of the eye due to minor eye irritations.
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
The robotic surgery program has continually pushed the boundaries of medical technology
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Becomes the first rehab & recovery center in east India to earn NABH accreditation
India Business grew by 11.9% YoY to Rs. 1196.2 crore
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Majority of organizations are looking to increase investments in public and hybrid cloud
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Subscribe To Our Newsletter & Stay Updated